5-hydroxytryptamine1A receptor density in the hippocampus of patients with temporal lobe epilepsy is associated with disease duration

Imagem de Miniatura
Arquivos
art_FONSECA_5hydroxytryptamine1A_receptor_density_in_the_hippocampus_of_patients_2017.PDF (303.14 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
Citação
EUROPEAN JOURNAL OF NEUROLOGY, v.24, n.4, p.602-608, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background and purpose: : To date, no study has evaluated the association between serotonin receptor density and clinical variables in patients with temporal lobe epilepsy caused by hippocampal sclerosis (TLE-HS) using hippocampal tissue. We evaluated 5-hydroxytryptamine1A receptor (5-HT1AR) density in hippocampal tissue from patients with TLE-HS. Methods: We analyzed the hippocampal tissue of 34 patients with pharmacoresistant unilateral TLE-HS. 5-HT1AR density was measured using semiquantitative western blotting. Results: There was an association between higher density of 5-HT1AR and longer duration of epilepsy (Spearman correlation: P = 0.040; generalized linear model: P = 0.026). Conclusions: This study demonstrated that hippocampal 5-HT1AR density is associated with epilepsy duration in patients with TLE-HS. The authors postulate that this may represent a potential regulatory enhancement of endogenous serotonergic neurotransmission in response to prolonged and enduring epileptiform activity in the hippocampal tissue of patients with pharmacoresistant TLE-HS.
Palavras-chave
epilepsy surgery, hippocampal sclerosis, hippocampus, refractory, serotonin, western blotting
URI
https://observatorio.fm.usp.br/handle/OPI/20159
Referências
  1. Assem-Hilger E, 2010, EPILEPSY BEHAV, V19, P467, DOI 10.1016/j.yebeh.2010.07.030
  2. Blumcke I, 2012, BRAIN PATHOL, V22, P402, DOI 10.1111/j.1750-3639.2012.00583.x
  3. Bogaert PV, 2001, EPILEPSY RES, V47, P127
  4. Browning RA, 1997, EUR J PHARMACOL, V336, P1, DOI 10.1016/S0014-2999(97)01215-6
  5. Chugani DC, 1998, ANN NEUROL, V44, P858, DOI 10.1002/ana.410440603
  6. Clinckers R, 2004, J NEUROCHEM, V89, P834, DOI 10.1111/j.1471-4159.2004.02355.x
  7. Clough R, 1996, NEUROREPORT, V8, P341, DOI 10.1097/00001756-199612200-00067
  8. da Fonseca NC, 2015, EPILEPSY RES, V111, P18, DOI 10.1016/j.eplepsyres.2014.12.013
  9. DAILEY JW, 1992, LIFE SCI, V50, P319, DOI 10.1016/0024-3205(92)90340-U
  10. DAILEY JW, 1989, EPILEPSY RES, V3, P3, DOI 10.1016/0920-1211(89)90063-6
  11. Didelot A, 2008, BRAIN, V131, P2751, DOI 10.1093/brain/awn220
  12. Filakovszky J, 1999, NEUROSCI LETT, V261, P89, DOI 10.1016/S0304-3940(99)00015-4
  13. Gariboldi M, 1996, BRIT J PHARMACOL, V119, P813
  14. Gerber K, 1998, BRAIN RES, V807, P243, DOI 10.1016/S0006-8993(98)00801-4
  15. Giovacchini G, 2005, J NUCL MED, V46, P1128
  16. Graebenitz S, 2011, BRAIN, V134, P2929, DOI 10.1093/brain/awr202
  17. Jakus R, 2003, EXP NEUROL, V184, P964, DOI 10.1016/S0014-4886(03)00352-2
  18. Jiang XL, 2009, NEUROPSYCHOPHARMACOL, V34, P410, DOI 10.1038/npp.2008.71
  19. Jobe PC, 2000, CNS DRUG REV, V6, P241
  20. Kim DS, 2007, BRAIN RES, V1154, P181, DOI 10.1016/j.brainres.2007.03.084
  21. Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x
  22. Liew CJ, 2009, EPILEPSIA, V50, P234, DOI 10.1111/j.1528-1167.2008.01789.x
  23. Lopez-Meraz ML, 2005, NEUROPHARMACOLOGY, V49, P367, DOI 10.1016/j.neuropharm.2005.03.020
  24. LOWRY OH, 1951, J BIOL CHEM, V193, P265
  25. Lu KT, 1998, NEUROSCIENCE, V86, P729, DOI 10.1016/S0306-4522(98)00106-7
  26. Mahmood Tahrin, 2012, N Am J Med Sci, V4, P429, DOI 10.4103/1947-2714.100998
  27. Marinova Z, 2015, NEUROPATH APPL NEURO, V41, P520, DOI 10.1111/nan.12167
  28. Martinez A, 2013, NEUROLOGY, V80, P1465, DOI 10.1212/WNL.0b013e31828cf809
  29. Palomero-Gallagher N, 2012, EPILEPSIA, V53, P1987, DOI 10.1111/j.1528-1167.2012.03634.x
  30. Pericic D, 2005, EUR J PHARMACOL, V527, P105, DOI 10.1016/j.ejphar.2005.10.021
  31. Rocha L, 2007, PROG NEURO-PSYCHOPH, V31, P1208, DOI 10.1016/j.pnpbp.2007.04.014
  32. Salgado-Commissariat D, 1997, NEUROPHARMACOLOGY, V36, P1705, DOI 10.1016/S0028-3908(97)00134-2
  33. Smolders I, 2008, NEUROPHARMACOLOGY, V54, P1017, DOI 10.1016/j.neuropharm.2008.02.006
  34. Speranza L, 2013, NEUROPHARMACOLOGY, V67, P155, DOI 10.1016/j.neuropharm.2012.10.026
  35. Statnick MA, 1996, NEUROPHARMACOLOGY, V35, P111, DOI 10.1016/0028-3908(95)00141-7
  36. Trottier S, 1996, EPILEPSY RES, V25, P79, DOI 10.1016/0920-1211(96)00033-2
  37. Vermoesen K, 2012, EPILEPSIA, V53, P870, DOI 10.1111/j.1528-1167.2012.03436.x
  38. Wada Y, 1997, BRAIN RES, V747, P338, DOI 10.1016/S0006-8993(96)01322-4
  39. WADA Y, 1993, NEUROSCI LETT, V159, P179, DOI 10.1016/0304-3940(93)90828-9
  40. Wang L, 2015, MOL NEUROBIOL, V51, P1292, DOI 10.1007/s12035-014-8806-6
  41. Watanabe K, 2000, EUR J PHARMACOL, V398, P239, DOI 10.1016/S0014-2999(00)00258-2
  42. YAN QS, 1994, EUR J PHARMACOL, V252, P105, DOI 10.1016/0014-2999(94)90581-9
  43. Yang ZY, 2012, EUR J PHARMACOL, V685, P52, DOI 10.1016/j.ejphar.2012.04.011

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21
Artigos e Materiais de Revistas Científicas - LIM/27